View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Balassa u. 6., 1083
  • | 2 Semmelweis Egyetem, Budapest
Open access

Absztrakt

A fájdalomcsillapító-túlhasználathoz társuló fejfájás a lakosság 1–2%-át érinti. Bármely fájdalomcsillapító rendszeres, havonta legalább 10 napon történő szedése kiválthatja, ezért minden olyan esetben gondolni kell rá, amikor korábban is panaszos betegek fejfájásának gyakorisága – nagyobb mennyiségben szedett fájdalomcsillapítók mellett – megnő. A kórkép leggyakrabban a 40–50 éves nőket érinti: kockázatát növeli a dohányzás, az elhízás, a depresszió, valamint a szorongásos zavar. Kialakulásában biológiai (genetikai megalapozottság, neurokémiai és neurofiziológiai eltérések) mellett pszichológiai, illetve életvezetési tényezők, így a fejfájásokra vonatkozó anticipátoros szorongás, a fájdalom katasztrofizálása, az ezek miatti kényszeres gyógyszerszedő magatartás is fontos szerepet játszanak. A fájdalomcsillapító-túlhasználathoz társuló fejfájás kezelésének elengedhetetlen része a kiváltó szer megvonása, a megvonási tünetek (köztük a rebound fejfájás) kezelése, a hatásos preventív terápia bevezetése, a komorbid betegségek kezelése, valamint a betegek megfelelő oktatása és pszichés támogatása. Mivel a visszaesés esélye megfelelő kezelés mellett is 30–40% lehet, alapvető fontosságú a megelőzés, amelyben az alapellátás szerepét nem lehet eléggé hangsúlyozni. Orv. Hetil., 2015, 156(30), 1195–1202.

  • 1

    Evers, S., Marziniak, M.: Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol., 2010, 9(4), 391–401.

  • 2

    Headache Classification Committee of the International Headache Society (IHS): The international classification of headache disorders, 3rd edition (beta version). Cephalalgia, 2013, 33(9), 629–808.

  • 3

    Horton, B. T., Peters, G. A.: Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: Report of 52 cases. Headache, 1963, 2, 214–227.

  • 4

    Kudrow, L.: Paradoxical effects of frequent analgesic use. Adv. Neurol., 1982, 33, 335–341.

  • 5

    Saper, J. R.: Drug abuse among headache patients. In: Saper, J. R. (ed.): Headache disorders: Current concepts and treatment strategies. John Wright Publishing, Boston, 1983.

  • 6

    Kaube, H., May, A., Pfaffenrath, V.: Sumatriptan. BMJ, 1994, 308(6943), 1573–1574.

  • 7

    Zwart, J. A., Dyb, G., Hagen, K., et al.: Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology, 2003, 61(2), 160–164.

  • 8

    Pascual, J., Colás, R., Castillo, J.: Epidemiology of chronic daily headache. Curr. Pain Headache Rep., 2001, 5(6), 529–536.

  • 9

    Evers, S., Jensen, R.: Treatment of medication overuse headache – guideline of the EFNS headache panel. Eur. J. Neurol., 2011, 18(9), 1115–1121.

  • 10

    Katsarava, Z., Obermann, M.: Medication-overuse headache. Curr. Opin. Neurol., 2013, 26(3), 276–281.

  • 11

    Linde, M., Gustavsson, A., Stovner, L. J., et al.: The cost of headache disorders in Europe: The Eurolight project. Eur. J. Neurol., 2012, 19(5), 703–711.

  • 12

    Diener, H. C., Dahlof, C. G.: Headache associated with chronic use of substances. In: Olesen, J., Tfelt-Hansen, P., Welch, K. M. A. (eds.): The headaches. 2nd ed. Lippincott, Williams & Wilkins, Philadelphia, 1999.

  • 13

    Evers, S., Suhr, B., Bauer, B., et al.: A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J. Neurol., 1999, 246(9), 802–809.

  • 14

    Wolfe, S., Van Stavern, G.: Characteristics of patients presenting with ocular pain. Can. J. Ophthalmol., 2008, 43(4), 432–434.

  • 15

    Ertsey, Cs.: Headache in everyday medical practice. [Fejfájás a mindennapi orvosi gyakorlatban.] Lege Artis Medicinae, 2010, 20(11), 727–731. [Hungarian]

  • 16

    Bigal, M. E., Serrano, D., Buse, D., et al.: Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache, 2008, 48(8), 1157–1168.

  • 17

    Ravishankar, K.: Medication overuse headache in India. Cephalalgia, 2008, 28(11), 1223–1226.

  • 18

    Tepper, S. J.: Medication-overuse headache. Continuum (Minneap. Minn.), 2012, 18(4), 807–822.

  • 19

    Katsarava, Z., Diener, H. C.: Medication overuse headache in Germany. Cephalalgia, 2008, 28(11), 1221–1222.

  • 20

    Mathew, N. T., Kurman, R., Perez, F.: Drug induced refractory headache – clinical features and management. Headache, 1990, 30(10), 634–638.

  • 21

    Cupini, L. M., De Murtas, M., Costa, C., et al.: Obsessive-compulsive disorder and migraine with medication-overuse headache. Headache, 2009, 49(7), 1005–1013.

  • 22

    Yoon, M. S., Manack, A., Schramm, S., et al.: Chronic migraine and chronic tension-type headache are associated with concomitant low back pain: results of the German Headache Consortium study. Pain, 2013, 154(3), 484–492.

  • 23

    De Tommaso, M., Sardaro, M., Serpino, C., et al.: Fibromyalgia comorbidity in primary headaches. Cephalalgia, 2009, 29(4), 453–464.

  • 24

    Yoon, M. S., Mueller, D., Hansen, N., et al.: Prevalence of facial pain in migraine: a population-based study. Cephalalgia, 2010, 30(1), 92–96.

  • 25

    Plesh, O., Noonan, C., Buchwald, D. S., et al.: Temporomandibular disorder-type pain and migraine headache in women: a preliminary twin study. J. Orofac. Pain, 2012, 26(2), 91–98.

  • 26

    Wilkinson, S. M., Becker, W. J., Heine, J. A.: Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache, 2001, 41(3), 303–309.

  • 27

    Paemeleire, K., Bahra, A., Evers, S., et al.: Medication-overuse headache in patients with cluster headache. Neurology, 2006, 67(1), 109–113.

  • 28

    Radat, F., Creac’h, C., Swendsen, J. D., et al.: Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia, 2005, 25(7), 519–522.

  • 29

    Hagen, K., Linde, M., Steiner, T. J., et al.: Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord Trøndelag Health Studies. Pain, 2012, 153(1), 56–61.

  • 30

    Scher, A. I., Stewart, W. F., Ricci, J. A., et al.: Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain, 2003, 106(1–2), 81–89.

  • 31

    Cevoli, S., Sancisi, E., Grimaldi, D., et al.: Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache, 2009, 49(3), 412–418.

  • 32

    Cevoli, S., Mochi, M., Scapoli, C., et al.: A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur. J. Neurol., 2006, 13(9), 1009–1013.

  • 33

    Di Lorenzo, C., Di Lorenzo, G., Sances, G., et al.: Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism. J. Headache Pain, 2009, 10(5), 349–355.

  • 34

    Di Lorenzo, C., Sances, G., Di Lorenzo, G., et al.: The wolframin His611Arg polymorphism influences medication overuse headache. Neurosci. Lett., 2007, 424(3), 179–184.

  • 35

    Cargnin, S., Viana, M., Ghiotto, N., et al.: Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. Eur. J. Neurol., 2014, 21(7), 989–995.

  • 36

    De Felice, M., Ossipov, M. H., Porreca, F.: Update on medication-overuse headache. Curr. Pain Headache Rep., 2011, 15(1), 79–83.

  • 37

    Srikiatkhachorn, A., Tarasub, N., Govitrapong, P.: Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache, 2000, 40(5), 343–350.

  • 38

    Coppola, G., Di Lorenzo, C., Schoenen, J., et al.: Habituation and sensitization in primary headaches. J. Headache Pain, 2013, 14, 65.

  • 39

    Coppola, G., Iacovelli, E., Bracaglia, M., et al.: Electrophysiological correlates of episodic migraine chronification: evidence for thalamic involvement. J. Headache Pain, 2013, 14, 76.

  • 40

    Riederer, F., Marti, M., Luechinger, R., et al.: Gray matter changes associated with medication-overuse headache: Correlations with disease related disability and anxiety. World J. Biol. Psychiatry, 2012, 13(7), 517–525.

  • 41

    Ferraro, S., Grazzi, L., Mandelli, M. L., et al.: Pain processing in medication overuse headache: a functional magnetic resonance imaging (fMRI) study. Pain Med., 2012, 13(2), 255–262.

  • 42

    Fumal, A., Laureys, S., Di Clemente, L., et al.: Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain, 2006, 129(2), 543–550.

  • 43

    Radat, F., Lanteri-Minet, M.: What is the role of dependence-related behavior in medication-overuse headache? Headache, 2010, 50(10), 1597–1611.

  • 44

    Peres, M. F., Mercante, J. P., Guendler, V. Z., et al.: Cephalalgiaphobia: a possible specific phobia of illness. J. Headache Pain, 2007, 8(1), 56–59.

  • 45

    Giannini, G., Zanigni, S., Grimaldi, D., et al.: Cephalalgiaphobia as a feature of high-frequency migraine: a pilot study. J. Headache Pain, 2013, 14, 49.

  • 46

    Fritsche, G., Frettlöh, J., Hüppe, M., et al.: Prevention of medication overuse in patients with migraine. Pain, 2010, 151(2), 404–413.

  • 47

    Cupini, L. M., De Murtas, M., Costa, C., et al.: Obsessive-compulsive disorder and migraine with medication-overuse headache. Headache, 2009, 49(7), 1005–1013.

  • 48

    Grazzi, L., Usai, S., Prunesti, A., et al.: Behavioral plus pharmacological treatment versus pharmacological treatment only for chronic migraine with medication overuse after day-hospital withdrawal. Neurol. Sci., 2009, 30(Suppl. 1), S117–S119.

  • 49

    Gunreben-Stempfle, B., Grießinger, N., Lang, E., et al.: Effectiveness of an intensive multidisciplinary headache treatment program. Headache, 2009, 49(7), 990–1000.

  • 50

    Gyüre, T., Csépány, É., Hajnal, B., et al.: The Comprehensive Headache-related Quality of life Questionnaire shows significant improvement after withdrawal treatment in medication overuse headache: a pilot study. [Az Átfogó Fejfájással Kapcsolatos Életminőség-kérdőív szignifikáns javulást mutat a gyógyszertúlhasználattal társuló fejfájás kezelése után: próbavizsgálat.] Ideggyogy. Sz., 2014, 67(5–6), 169–176.

  • 51

    Rossi, P., Jensen, R., Nappi, G., et al.: A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J. Headache Pain, 2009, 10(6), 407–417.

  • 52

    Obermann, M., Katsarava, Z.: Management of medication-overuse headache. Expert Rev. Neurother., 2007, 7(9), 1145–1155.

  • 53

    Pageler, L., Katsarava, Z., Diener, H. C., et al.: Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia, 2008, 28(2), 152–156.

  • 54

    Rabe, K., Pageler, L., Gaul, C., et al.: Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia, 2013, 33(3), 202–207.

  • 55

    Diener, H. C., Katsarava, Z.: Analgesic/abortive overuse and misuse in chronic daily headache. Curr. Pain Headache Rep., 2001, 5(6), 545–550.

  • 56

    Schwartz, T. H., Karpitskiy, V. V., Sohn, R. S.: Intravenous valproate sodium in the treatment of daily headache. Headache, 2002, 42(6), 519–522.

  • 57

    Diener, H. C., Bussone, G., Van Oene, J. C., et al.: Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia, 2007, 27(7), 814–823.

  • 58

    Silberstein, S. D., Lipton, R. B., Dodick, D. W., et al.: Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache, 2007, 47(2), 170–180.

  • 59

    Munksgaard, S. B., Jensen, R. H.: Medication overuse headache. Headache, 2014, 54(7), 1251–1257.

  • 60

    Silberstein, S. D., Blumenfeld, A. M., Cady, R. K., et al.: Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J. Neurol. Sci., 2013, 331(1–2), 48–56.

  • 61

    Grazzi, L., Andrasik, F., D’Amico, D., et al.: Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache, 2002, 42(6), 483–490.

  • 62

    Gaul, C., van Doorn, C., Webering, N., et al.: Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J. Headache Pain, 2011, 12(4), 475–483.

  • 63

    Wallasch, T. M., Kropp, P.: Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study. J. Headache Pain, 2012, 13(7), 521–529.

  • 64

    Management of medication overuse headache. BMJ, 2010, 340, c1305.

  • 65

    Katsarava, Z., Muessig, M., Dzagnidze, A., et al.: Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia, 2005, 25(1), 12–15.

  • 66

    Rossi, P., Faroni, J. V., Nappi, G.: Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia, 2008, 28(11), 1196–1200.

  • 67

    Russell, M. B., Lundqvist, C.: Prevention and management of medication overuse headache. Curr. Opin. Neurol., 2012, 25(3), 290–295.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 167 142 21
PDF Downloads 141 121 14